We are international
Donate
TEXT SIZE   


Myeloma Minute
September 24, 2015
09.24.15
September 24, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
   

 
This week's question: Do African Americans have an increased risk of myeloma?


Multiple Myeloma Bone Study

New Selinexor STORM Clinical Trials: Learn How To Participate

New Ixazomib Clinical Trials: Learn How To Participate

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events

Saturday, September 26, 2015
 Miracles for Myeloma 3rd Annual 5k Run/Walk

Clark, New Jersey

Saturday, September 26, 2015
3rd Annual Visit to Virginia's Wine Country
Midlothian, Virginia


Saturday, October 10, 2015
 9th Annual Comedy Celebration

Los Angeles, California

 

 

Saturday, November 14, 2015
Regional Community Workshop

Washington D.C.

 

Saturday, November 21, 2015
Regional Community Workshop

Chicago, Illinois


Watch the IMF Mambo for Myeloma & Support This Challenge

    

x

New Study Investigates Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

The results of the first clinical trial to investigate carfilzomib (Kyprolis®), pomalidomide (Pomalyst®), and dexamethasone (CPD) in multiple myeloma were published last week in the journal BLOOD . IMF Chairman Dr. Brian Durie, co-author of the study, calls the phase I-II results “remarkably good.” According to Dr. Durie, the well-tolerated regime produces remissions lasting approximately one year, and overall survival of close to two years, in the very-poor-risk setting of double refractory disease in which patients are resistant to both lenalidomide (Revlimid®) and bortezomib (Velcade®).

 

“As we continue to search for new agents to fulfill the ‘unmet need’ of rescue therapy—when all else has failed—the CPD regimen is an attractive, available option which can be broadly offered to such patients,” he notes. “Moving forward, combinations of CPD incorporating monoclonal antibodies or other immune therapies are potential approaches to achieve even longer remissions and survival. Used in the setting of resistant minimal residual disease, rather than at the point of frank relapse, even better results can be anticipated, which is one of the goals of the Black Swan Research Initiative®.” To read an abstract of the study, click HERE.

 

x

Comedian Tig Notaro to Perform at IMF's 9th Annual Comedy Celebration



 

Celebrated comic Tig Notaro will perform at this year's 9th Annual Comedy Celebration gala. Tig’s honest and humorous take on life after her own cancer diagnosis have quickly made her a cult icon. Silent auction items for the event include an 8-day European Viking river cruise and, for Downton Abbey fans, a dinner with Mrs. Patmore character actress Lesley Nicol, IMF President Susie Novis and IMF Chairman Dr. Brian Durie in their home.  Hard-to-come-by Saturday Night Live tickets will go to the highest bidder! Proceeds from the event benefit the Peter Boyle Research Fund, as well as support the Black Swan Research Initiative®, the IMF's collaborative project aimed at developing the first definitive cure for myeloma. The night kicks off at 6 pm, Saturday, October 10 at the Wilshire Ebell Theatre & Club in Los Angeles. You can purchase tickets HERE.

x

IMF Nurse Leadership Board Members Answer Top Myeloma Questions



 

Frequently asked myeloma questions will be answered at the upcoming “Living Well With Myeloma” teleconference on Thursday, October 8. “Nurse Leadership Board Members Address Patient and Caregiver Questions” is the title of this informative teleconference, featuring speakers Beth Faiman PhD, APRN-BC, AOCN® and Teresa Miceli, RN, BSN, OCN®. These dedicated myeloma nurses tackle the questions of myeloma patients and caregivers every day and will share the latest myeloma updates as well as answer questions. The 60-minute teleconference begins at 4 pm PT/7 pm ET. To register, please click, click HERE.

 

x

Missed the Veterans Against Myeloma Webinar? Watch the Replay on IMF TV


 

There was a great live turnout for the IMF’s recent “Veterans Against Myeloma Teleconference Series” webinar titled “The Military Veteran’s Perspective on Living with Multiple Myeloma.” The session featured an informative presentation, as well as Q & A session, with Sandy Kurtin, RN, MS, AOCN®, ANP and Susan Leigh, RN, retired Lieutenant, US Army, and Vietnam Veteran. Topics included the results of the IMF’s Veterans Against Myeloma focus group, current trends in multiple myeloma treatment, and strategies for veterans to optimize their access to resources. If you missed the live event, you can watch the video reply on IMF TV, HERE.

x

Upcoming Regional Community Workshops Announced for Washington D.C. and Chicago

 

Regional Community Workshops are informative half-day meetings designed to provide much of the same myeloma information as a Patient & Family Seminar, but in a condensed form. Upcoming workshops have just been announced for the Washington D.C. and Chicago, Illinois areas. The Washington D.C. workshop will take place on Saturday, November 14 from 9:30 AM to 3:00 PM at the Westin City Center and will feature speakers Dr. David Vesole, Professor of Medicine, Georgetown University; Dr. Rafat Abonour, Professor of Medicine, Indiana University, and Ann McNeill, RN, MSN, APN-C, John Theurer Cancer Center. The Chicago area workshop will take place on Saturday, November 21 from 9:30 AM to 3:00 PM at the Westin North Shore and will also feature speaker Dr. Rafat Abonour, as well as Joseph Tariman, Phd, ANP-BC, De Paul University. Both events are free, but you must register to reserve your seat by clicking on the link of the workshop you’d like to attend. 

 

 

 


Join Our Mailing List

 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

.


 related articles